Those results are in vitro. WE haven't even hit the in vivo stage
This is a reason why we can't even go the Barda route as in vivo is a requirement now. Leo confirmed Barda wasn't an option on my call but there were many other funding opps to chose from. He said based on the normal timeframe we should have heard by mid-September. It's now late October. Based on that comment, it doesn't seem like we are making it to in vivo through the RBL
Ipix was granted a pre-ind meeting but doesn't mean our journey will progress into an ind - leo finds the pen mightier then the sword (ipix track record). Many pinksheet, i mean otc ceos when pushed will tell you they went public to tap the markets. No better way then to keep dangling a carrot infront of investors
At least i need the write off by end of year if this doesn't pan out; can't believe i am saying this after all the pr's
Leo should focus on OM/UP now... He had his chance and blew it with the RBL delays... Couple of Vaccines due out soon will all but close the door on this fantasy. Not receiving grant money or high priority from the lab was the turning point (lower) for the stock rally. Then silence on the Aspire agreement as if nobody would notice? Many press releases and there's still more questions now than 2 months ago.
Market Data 
Markets 
AI
